Flanvotumab

Flanvotumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	HGF
Clinical data
ATC code	none;
Identifiers
CAS Number	1188277-05-5 ;
ChemSpider	none;
UNII	ZNV4738BS6;
Chemical and physical data
Formula	C6470H9986N1714O2018S46
Molar mass	145545.80 g·mol−1
	(what is this?) (verify)

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.^[1] It targets TYRP1.^[2]

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.^[2]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
^ ^a ^b "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Flanvotumab
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.

[Adis-2] "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.

[1]

[2]